Methyl 3-(aminomethyl)-5-methylhexanoate | 1201805-54-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl 3-(aminomethyl)-5-methylhexanoate
• CAS: 1201805-54-0
• 化学式: C₉H₁₉NO₂
• 分子量: 173.25
• InChiKey: JDFPGFRTUSUWNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] TRANSAMINASE-BASED PROCESSES FOR PREPARATION OF PREGABALIN<br/>[FR] PROCÉDÉS À BASE DE TRANSAMINASE UTILISÉS DANS LA PRÉPARATION DE LA PRÉGABALINE
  申请人：BIOVERDANT INC

  公开号：WO2008127646A2

  公开（公告）日：2008-10-23

  (EN) Provided herein are compounds and processes to prepare intermediates and precursors of pregabalin and related compositions, and processes for the preparation of pregabalin.(FR) Cette invention a trait à des composés et des procédés permettant de préparer des composés intermédiaires et des précurseurs de la prégabaline ainsi que des compositions associées; l'invention concerne également des procédés de préparation de la prégabaline.
• [EN] NOVEL RESOLUTION PROCESS FOR PREGABALIN<br/>[FR] NOUVEAU PROCÉDÉ DE RÉSOLUTION POUR LA PRÉGABALINE
  申请人：NATCO PHARMA LTD

  公开号：WO2009044409A2

  公开（公告）日：2009-04-09

  Present invention relates to a novel and improved process for the resolution of racemic pregabalin of formula (I) into (S)-(+)-pregabalin [(S)-(+)-3-aminomethyl-5-methylhexanoic acid] of formula (III) via the novel acid addition salt [(S)-(+) 3-aminomethyl-5-methylhexanoic acid, (-)-O, O'-di-p-toluoyl-L-tartaric acid salt] of formula (II). (S)-(+)-pregabalin of formula-III has analgesic, anticonvulsant and anxiolytic properties and hence is of great therapeutic significance.
• [EN] A NOVEL PROCESS FOR SYNTHESIS OF PREGABALIN FROM SUBSTITUTED CYCLOPROPANE INTERMEDIATE AND A PROCESS FOR ENZYMATIC RESOLUTION OF RACEMIC PREGABALIN<br/>[FR] NOUVEAU PROCÉDÉ DE SYNTHÈSE DE LA PRÉGABALINE À PARTIR D'UN INTERMÉDIAIRE CYCLOPROPANE SUBSTITUÉ ET PROCÉDÉ POUR LA RÉSOLUTION ENZYMATIQUE DE LA PRÉGABALINE RACÉMIQUE
  申请人：VB MEDICARE PVT LTD

  公开号：WO2009087650A2

  公开（公告）日：2009-07-16

  A novel process of preparation of racemic pregabalin from comprising an intermediate of structure III comprising reductive ring opening to form a structure IV followed few alternative routes that yield racemic pregabalin that is resolved to yield (S) + pregabalin by using chemical or enzymatic methods. A new chemical entity of structure IIIc is also disclosed as a novel intermediate. A part of the novel process also comprises a new process of producing a compound of structure VII comprising acylation of compound of structure V followed by elimination and improving a process of producing a compound of structure VII comprising reacting isovaleraldehyde with nitromethane through the compounds 4-methyl-1-nitropentan- 2-ol, 3-methyl-1-(nitromethyl)butylacetate, and 3-methyl-1-(nitromethyl)butyl acetate under suitable conditions to 4-methyl-1-nitropet-1-ene. Enzymatic processes of resolution of racemic pregabalin esters into (S) pregabalin and (R) pregabalin are also disclosed.
• [EN] COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS<br/>[FR] COMPOSÉS ET PROCÉDÉS DE TRAITEMENT DE TROUBLES OCULAIRES
  申请人：UNIV CASE WESTERN RESERVE

  公开号：WO2011071995A2

  公开（公告）日：2011-06-16

  A method of treating an ocular disorder in a subject associated with aberrant all-trans-retinal clearance in the retina, the method comprising administering to the subject a therapeutically effective amount of a primary amine compound of formula: wherein R1 is an aliphatic and/or aromatic compound; the primary amine compound upon administration to the subject forming a reversible Schiff-base with theall-trans-retinal or its metabolite including A2E and retinal dimer without adversely affecting normal retinoid cycle performance; the primary amine compound when administered to a Rdh8-1-Abca4-1- mouse increasing the optical coherence tomography score of the mouse to at least about 2.5 and increasing 11-ds-retinal amount at least about 30% in comparison to untreated control animal, wherein the primary amine compound is not a local anesthetic, which includes an aromatic amine, that demonstrates sodium channel blockade when administered to the subject.